Monument Therapeutics is a spin out from Cambridge Cognition advancing small molecules paired with a digital biomarker through phase I clinical trials, to address significant challenges in central nervous system (CNS) drug discovery.

Neuroscience has the potential to be in the ’20s what oncology has been in the last decade